瑞舒伐他汀对脑梗死合并颈动脉粥样硬化患者神经功能缺损及血清hs-CRP、IL-6的影响

目的探讨瑞舒伐他汀治疗脑梗死合并颈动脉粥样硬化患者的神经功能缺损及血清hs—CRP、IL-6的变化。方法：以我院收治的符合纳入标准的患者176例作为研究对象，随机分为A组和B组各88例，B组采用常规治疗，A组患者在常规治疗基础上服用瑞舒伐他汀（10 mg／d），2组疗程均为6个月。采用美国国立卫生研究院卒中量表（NIHSS）、改良RANKIN量表（mRS）评分及血清hs—CRP、IL-6的变化评价疗效。结果：治疗后A组患者血清ha—ClIP、IL-6水平均显著低于B组（P〈0．05）。治疗后2组mRS评分比较差异无统计学意义（P〉0，05），而A组的NIHSS评分〈B组（P〈0．05）。结论：瑞舒伐他汀可通过减少炎症因子的释放、改善内皮功能而减少炎症反应，在减缓动脉粥样硬化进程的同时有效减少了脑梗死对神经功能的损害。

Objective To study the changes of neurological function and serum hs-CRP and IL-6 in patients with cerebralinfarction complicated by carotid atherosclerosis treated with rosuvaatatin, Methods： 176 patients were randomly assigned togroup A and group B, 88 cases in each group. Both groups were treated with conventional treatment for six months, whilerosuvastatin was prescribed in group A during the whole treament, The U,S. National Institutes of Health Stroke Scale （NIHSS）,modified RANKIN scale （mRS） score, serum hs-CRP and IL-6 were analyzed between the two groups before arid after treatroent.Results： After the treatment, the serum levels of IL-6 and hs-CRP in the two gronpa were decreased, the changes in group Awas significantly lower than that in group B （P 〈0,05）, There was no significant difference in mRS score between the two groups（P 〉 0.05）. Compared with group B, the NIHSS score in the groupA was lower （P〈0-5）. Conclusion： Rosuvastatin can reduceinflammatory reaction by reducing the release of inflammatory factors and improve endothelial function. Meanwhile, rosuvastatincan effectively reduce the damage of cerebral infarction on neurological function by slowing the progression of atherosclerosis.